首页 | 本学科首页   官方微博 | 高级检索  
     


Biomarkers for Monitoring Pre-Analytical Quality Variation of mRNA in Blood Samples
Authors:Hui Zhang  Vlasta Korenková   Robert Sj?back  David ?vec  Jens Bj?rkman  Mogens Kruh?ffer  Paolo Verderio  Sara Pizzamiglio  Chiara Maura Ciniselli  Ralf Wyrich  Uwe Oelmueller  Mikael Kubista  Torbj?rn Lindahl  Anders L?nneborg  Edith Rian
Affiliation:1. DiaGenic ASA, Oslo, Norway.; 2. Laboratory of Gene Expression, Institute of Biotechnology, Academy of Sciences of the Czech Republic, Prague, Czech Republic.; 3. TATAA Biocenter, Gothenburg, Sweden.; 4. AROS Applied Biotechnology AS, Aarhus, Denmark.; 5. Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milano, Italy.; 6. Qiagen GmbH, Hilden, Germany.; The University of Hong Kong, Hong Kong,
Abstract:There is an increasing need for proper quality control tools in the pre-analytical phase of the molecular diagnostic workflow. The aim of the present study was to identify biomarkers for monitoring pre-analytical mRNA quality variations in two different types of blood collection tubes, K2EDTA (EDTA) tubes and PAXgene Blood RNA Tubes (PAXgene tubes). These tubes are extensively used both in the diagnostic setting as well as for research biobank samples. Blood specimens collected in the two different blood collection tubes were stored for varying times at different temperatures, and microarray analysis was performed on resultant extracted RNA. A large set of potential mRNA quality biomarkers for monitoring post-phlebotomy gene expression changes and mRNA degradation in blood was identified. qPCR assays for the potential biomarkers and a set of relevant reference genes were generated and used to pre-validate a sub-set of the selected biomarkers. The assay precision of the potential qPCR based biomarkers was determined, and a final validation of the selected quality biomarkers using the developed qPCR assays and blood samples from 60 healthy additional subjects was performed. In total, four mRNA quality biomarkers (USP32, LMNA, FOSB, TNRFSF10C) were successfully validated. We suggest here the use of these blood mRNA quality biomarkers for validating an experimental pre-analytical workflow. These biomarkers were further evaluated in the 2nd ring trial of the SPIDIA-RNA Program which demonstrated that these biomarkers can be used as quality control tools for mRNA analyses from blood samples.
Keywords:
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号